Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind active- and placebo-controlled study of a 15-valent recombinant HPV vaccine in healthy Chinese participants aged 9-45 years
CTR20244986Phase 2Completed
- Sponsor
- Biowell
- Start
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 15-valent recombinant human papillomavirus vaccine in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma and 13 more (3 arms), sponsored by Biowell. Started Jan 2025; status: completed.
02
Drugs
15-valent recombinant human papillomavirus vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal canceroropharyngeal cancer
Beyond the preview
Go deeper on CTR20244986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244986.